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Abstract
Anorexia nervosa (AN) is a complex and heritable eating disorder characterized by dangerously 
low body weight. Neither candidate gene studies nor an initial genome wide association study 
(GWAS) have yielded significant and replicated results. We performed a GWAS in 2,907 cases 
with AN from 14 countries (15 sites) and 14,860 ancestrally matched controls as part of the 
Genetic Consortium for AN (GCAN) and the Wellcome Trust Case Control Consortium 3 
(WTCCC3). Individual association analyses were conducted in each stratum and meta-analyzed 
across all 15 discovery datasets. Seventy-six (72 independent) SNPs were taken forward for in 
silico (two datasets) or de novo (13 datasets) replication genotyping in 2,677 independent AN 
cases and 8,629 European ancestry controls along with 458 AN cases and 421 controls from 
Japan. The final global meta-analysis across discovery and replication datasets comprised 5,551 
AN cases and 21,080 controls. AN subtype analyses (1,606 AN restricting; 1,445 AN binge-
purge) were performed. No findings reached genome-wide significance. Two intronic variants 
were suggestively associated: rs9839776 (P=3.01×10-7) in SOX2OT and rs17030795 
(P=5.84×10-6) in PPP3CA. Two additional signals were specific to Europeans: rs1523921 
(P=5.76×10-6) between CUL3 and FAM124B and rs1886797 (P=8.05×10-6) near SPATA13. 
Comparing discovery to replication results, 76% of the effects were in the same direction, an 
observation highly unlikely to be due to chance (P=4×10-6), strongly suggesting that true findings 
exist but that our sample, the largest yet reported, was underpowered for their detection. The 
accrual of large genotyped AN case-control samples should be an immediate priority for the field.
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Introduction
Anorexia nervosa (AN) is a perplexing biologically-influenced psychiatric disorder 
characterized by the maintenance of dangerously low body weight, fear of weight gain, and 
seeming indifference to the seriousness of the illness.1 AN affects ∼1% of the 
population.2, 3 Females are disproportionately afflicted, although males also develop the 
condition.4 The most common age of onset is 15-19 years;5 however, the incidence appears 
to be increasing in the pre-pubertal period6 and in older adults.7 AN is often comorbid with 
major depressive disorder, anxiety disorders, and multiple somatic complications.8-12 
Although most individuals recover, ∼25% develop a chronic and relapsing course.13 AN 
ranks among the ten leading causes of disability among young women14 and has one of the 
highest mortality rates of any psychiatric disorder.15-19 The evidence base for treatment for 
AN has been described as “weak,”20, 21 and treatment and extended inpatient 
hospitalizations for weight restoration are costly.22, 23 In sum, the public health impact of 
AN is considerable, and AN carries substantial morbidity, mortality, and personal, familial, 
and societal costs.
As with most idiopathic psychiatric disorders, the inheritance of AN is complex. The core 
features of AN [i.e., the ability and determination to maintain low body mass index (BMI)] 
are remarkably homogeneous across time and cultures.24, 25 Genetic epidemiological studies 
have documented the familiality of AN (relative risk 11.3 in first-degree relatives of AN 
probands)26, 27 and the estimated twin-based heritability of AN ranges from 33 to 84%.28-32 
Genome-wide linkage studies did not narrow the genomic search space in a compelling 
manner.33-35 Findings from candidate gene studies of AN resemble those for most complex 
biomedical diseases—initial intriguing findings diminished by the absence of rigorous 
replication.36-38
Given the centrality of weight dysregulation to AN, genes implicated in the regulation of 
body weight might also be involved in the etiology of AN.39, 40 Therefore genetic variants 
with a profound effect on BMI are worthy of consideration.38
Two genome-wide association studies (GWAS) of AN have been conducted. One study that 
used DNA pooling and genotyping with a modest number of microsatellite markers with 
follow-up genotyping detected evidence for association with rs2048332 on chromosome 1, 
but this finding did not reach genome-wide significance.41 A GWAS of 1033 AN cases from 
the USA, Canada, and Europe compared with 3733 pediatric controls yielded no genome-
wide significant findings.42 Recently, a sequencing and genotyping study of 152 candidate 
genes in 1205 AN cases and 1948 controls suggested a novel association of a cholesterol 
metabolism influencing EPHX2 gene with susceptibility to AN.43
In recognition of the need for large-scale sample collections to empower GWAS, we 
established the Genetic Consortium for Anorexia Nervosa (GCAN) in 2007—a worldwide 
collaboration combining existing DNA samples of AN patients into a single resource. As 
part of the Wellcome Trust Case Control Consortium 3 (WTCCC3), we have conducted the 
largest GWAS for AN to date.
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Materials and Methods
Discovery dataset
We conducted a GWAS across 15 discovery datasets, comprising a total of 2,907 AN cases 
and 14,860 ancestrally matched controls of European origin (Table 1). All AN cases were 
female. Diagnostic determination was via semi-structured or structured interview or 
population assessment strategy based on DSM diagnostic criteria. Cases met DSM-IV 
criteria for lifetime AN (restricting or binge-purge subtype) or lifetime DSM-IV eating 
disorders “not otherwise specified” (EDNOS) AN-subtype (i.e., exhibiting the core features 
of AN). We did not require the presence of amenorrhea as this criterion does not increase 
diagnostic specificity.44, 45 Given the frequency of diagnostic crossover, a lifetime history of 
bulimia nervosa was allowed.46 Exclusion criteria included the diagnosis of medical or 
psychiatric conditions that might have confounded the diagnosis of AN (e.g., psychotic 
disorders, mental retardation, or a medical or neurological condition causing weight loss). 
Controls were carefully selected to match for ancestry within each site and chosen primarily 
from existing GWAS genotypes through collaboration and genotyping repository (dbGAP) 
access. Each site obtained ethical approval from the local ethics committee, and all 
participants provided written informed consent in accordance with the Declaration of 
Helsinki.
Genotyping, imputation and quality control
AN cases from the 15 sites were genotyped using Illumina 660W-Quad arrays (Illumina, 
Inc., San Diego, CA, USA) at the Wellcome Trust Sanger Institute. Funding was available 
only for genotyping AN cases. Thus, control genotypes were selected from existing datasets 
matched as closely as possible to the ancestry of cases and Illumina arrays as similar as 
possible to the 660W array (Table S1). Quality control (QC) of directly typed variants was 
performed within each of the 15 case-control datasets (Table S2, Supplementary 
Information).
Phasing and imputation was performed separately for each of the 15 datasets using a 
common set of single nucleotide polymorphisms (SNPs) passing QC (Table S2) using the 
program Impute2 v2.1.2 (Supplementary Information).47 The imputation reference panel 
was HapMap 3 release 2. We used all available HapMap3 populations for imputation as it 
was shown that the increase in the reference panel decreases error.48, 49 Post-imputation 
filters were applied to remove SNPs with INFO scores < 0.4 or with MAF < 0.05. We 
observe high imputation accuracy (as captured by the INFO score) across a range of minor 
allele frequencies (Figure S1). There was high concordance between directly genotyped 
variants with imputed dosages of the same variants after masking (Figure S2).
Statistical analysis
Single-SNP association analyses were performed under an additive genetic modelseparately 
within each of the 15 datasets (Supplementary Information). We tested for association across 
the autosomes and the non-pseudoautosomal region of the X chromosome. Imputation and 
association analysis of the non-pseudoautosomal region of the chromosome X data were 
based on females (2,907 AN cases and 10,594 controls). Association analyses were 
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performed using SNPTEST v2.2.049 under an additive model and using a score test. To 
guard against false positives due to population stratification, we carried out association 
analysis within each dataset and then combined the results using meta-analysis (for the 
French dataset, the first principal component was added as a covariate). Fixed-effects meta-
analyses were performed using GWAMA.50 All 15 discovery datasets were corrected for the 
genomic control (GC) inflation factor (λGC) prior to performing meta-analysis (Table S2; 
Supplementary Information).
Replication
We prioritized directly genotyped and imputed SNPs for replication based on statistical 
significance (P < 10-4), robust QC metrics, and vicinity to plausible candidate genes. In total 
96 SNPs (95 autosomal and one on chromosome X) in 66 genomic regions showed nominal 
evidence for association. We selected 72 independent, uncorrelated variants representing 
each of the 66 associated genomic regions and added 4 proxies for the most associated SNPs 
resulting in 76 SNPs for replication. Cluster plots of all prioritized SNPs were examined 
using Evoker51 in cases and controls separately to minimize the possibility of spurious 
association due to genotyping error. We included 27 ancestry-informative markers (AIMs) 
for genotyping in the replication datasets, to guard against population stratification 
(Supplementary Information).52
Our replication data included 15 datasets—two existing in silico datasets and 13 datasets for 
de novo genotyping (Table 1). The in silico dataset from the USA came from an existing 
GWAS of AN genotyped using the Illumina HumanHap610 platform (Illumina, San Diego, 
CA, USA)53 and the other in silico dataset came from Estonian Genome Center 
(www.biobank.ee) and was genotyped using the Illumina OmniExpress array. De novo 
genotyped samples included newly collected AN cases and controls from members of the 
GCAN and samples from the same sites as the discovery samples that had failed GWAS QC 
(including saliva and whole genome amplified samples). De novo SNP genotyping was 
carried out using the iPLEX Gold Assay (Sequenom, Inc., San Diego, CA, USA). SNPs with 
poor Sequenom design metrics were replaced with high-LD proxies. Sample and SNP QC 
were performed within each replication dataset. QC included checking for sex 
inconsistencies and exclusions based on sample call rate <80%, SNP call rate <90% and 
exact Hardy-Weinberg Equilibrium (HWE) p<0.0001. In total, replication genotypes (in 
silico and de novo) of 76 prioritized SNPs and 27 AIMs were available from 2,677 AN cases 
and 8,629 controls of European ethnicity and 458 AN cases and 421 controls from Japan.
Association analyses of prioritized SNPs were performed under an additive genetic model 
within each replication dataset with and without adjustment for AIMs. AIMs that showed 
nominally significant p-values for allele frequency differences between de novo typed cases 
and controls were used for conditional analysis (Table S3). As there were no qualitative 
differences between these results, the main text reports the unadjusted results. The USA 
replication dataset contained individuals who were related to individuals from the USA 
discovery dataset. As such, those samples were excluded from the discovery dataset and 
combined with replication USA samples to correctly account for relatedness between 
samples for the final global meta-analysis and sign test. Software packages GenABEL54 and 
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GEMMA55 were used for replication analysis of the USA dataset. Fixed-effects meta-
analysis across the replication datasets was performed using GWAMA50 (with and without 
adjustment for AIMs and in samples of European ancestry only, i.e., excluding Japan, also 
with and without adjustment for AIMs). We also performed meta-analyses across the 
discovery and replication datasets, comprising a total of 5,551 AN cases and 21,080 controls 
(USA discovery samples were included only once as part of the replication phase). We 
calculated the power of the final global meta-analysis using QUANTO.56
Seventy-two independent SNPs were used to compare the direction of effects between the 
discovery and replication meta-analyses using R.57 For this analysis, the USA samples were 
used only once as part of the replication meta-analysis.
Additional analyses
We performed three additional analyses: 1) genome-wide complex trait analysis (GCTA), 
designed to estimate the proportion of phenotypic variance explained by genome-wide SNPs 
for complex traits,58 a network analysis, and a gene-based association test (Supplementary 
Information).
AN subtype analyses
Two subtype (Supplementary Information) association analyses were performed for the 76 
prioritized SNPs across the discovery and replication datasets (Table 1). In total, the AN 
restricting subtype global meta-analysis included 1,606 cases and the AN binge-purge 
subtype analysis included 1,445 cases. Both analyses used the same set of 16,303 controls 
(Supplementary Information).
Related traits
Using the discovery meta-analysis, we investigated evidence for association using SNP 
results from published studies: 9 SNPs with nominal evidence of association with AN;42 14 
SNPs suggestively associated with eating disorder-related symptoms, behaviors, or 
personality traits;59, 60 89 SNPs with genome-wide significance in studies of BMI or 
obesity;61, 62 and 15 SNPs related to morbid obesity.61 We also investigated evidence for 
association across the 72 replication SNPs using published GWAS results from the 
Psychiatric Genomics Consortium (https://pgc.unc.edu) for attention-deficit/hyperactivity 
disorder (ADHD), schizophrenia, bipolar disorder, and major depressive disorder.63-66
Expression studies
We prioritized the top 20 SNPs in terms of statistical significance and quantified the 
expression of the two nearest genes per SNP (Table S4) in 12 inbred strains of mice. We 
obtained publicly available RNAseq data from whole brain tissue samples and used standard 
software to map and count the sequence reads (Supplementary Information).
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Results
Main association results
Of 1,185,559 imputed SNPs that passed QC, 287 showed evidence for association in the 
discovery stage with P < 10-4. These variants represented 66 independent signals and had 
frequencies and effect sizes commensurate with observations in other common complex 
diseases. One variant, not surrounded by other SNPs achieving low p-values and for which 
genotypes were only available in two of the 15 initial study groups, surpassed genome-wide 
significance (rs4957798, P=1.67×10-12) but was not subsequently replicated in the global 
meta-analysis across discovery and replication samples. The overall λGC was 1.03 (Figures 
S3 and S4).Seventy-six SNPs (of which 72 were independent) were prioritized for follow-up 
through in silico and de novo replication (Table S5). Nine SNPs showed association with P 
< 0.05 (minimum p-value was 0.003) in the replication dataset meta-analysis (binomial 
P=0.0135) (Table S5). Based on 72 independent SNPs taken forward, we would expect 
0.05×72=3.6 SNPs to reach P=0.05 by chance. The 0.0135 P value reflects this enrichment 
in signal. No signals surpassed genome-wide significance (P=5×10-8) in the final global 
meta-analysis across all discovery and replication samples (Table S5) or in the AN subtype 
analyses (Tables S6-S7).
Of critical importance, we observed significant evidence of SNP effect sizes in the 
replication data in the same direction as the discovery set (55/72 signals, sign test binomial 
P=4×10-6). This enrichment was also observed for the AN restricting (58/72, P=8×10-8) and 
binge-purge (56/72, P=1×10-6) subtype analyses. These results strongly indicate that the 
prioritized set of variants is likely to contain true positive signals for AN but that the current 
sample size is insufficient to detect these effects.
Our analysis revealed two notable variants: rs9839776 (P=3.01×10-7) in SOX2OT (SOX2 
overlapping transcript) and rs17030795 (P=5.84×10-6) in PPP3CA (protein phosphatase 3, 
catalytic subunit, alpha isozyme) (Table 2). Two additional signals emerged from the 
analysis focused on European replication samples only: rs1523921 (P=5.76×10-6) located 
between CUL3 (cullin 3) and FAM124B (family with sequence similarity 124B) and 
rs1886797 (P=8.05×10-6) located 18kb from SPATA13 (spermatogenesis associated 13) 
(Table S5). Four signals were in neurodevelopmental genes regulating synapse and neuronal 
network formation (SYN2, NCAM2, CNTNAP2 and CTNNA2; Table 2).
AN subtype analyses
In the AN restricting subtype analyses, the two most significant signals were rs1523921 (as 
in the main analysis, P=8.39×10-5) and rs10777211 (P=8.95×10-5) located 333kb from 
ATP2B1 (ATPase, calcium transporting, plasma membrane 1), both detected in the 
European-only analysis (Table S6). The most significant result for AN binge-purge analysis 
was rs9839776 (as in the main analysis, P=3.97×10-4) in SOX2OT, also in Europeans only 
(Table S7). Overall, signals from the main AN case-control analysis display similar levels of 
association across both AN subtypes (Table S8).
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Additional analyses
GCTA is technically challenging when synthesizing data across multiple strata with small 
individual sample sizes. When we applied it to our data we saw great variability in the 
estimates of variance and did not judge the results reliable. Results of the gene-based 
association test and network analysis are presented in their entirety in Supplemental 
Information and Figure S5, both of which were unremarkable.
Related traits
Nine out of the 11 previously reported variants suggestively associated with AN42 were 
found in our discovery meta-analysis, and six of these 9 SNPs had the same direction of 
effect as originally reported (P=0.508) (Table S9). Twelve out of 14 variants previously 
reported to be associated with eating disorder-related symptoms, behaviors, and personality 
traits59, 60 were found in our discovery meta-analysis and 7 had the same direction of effect 
(P=0.774) (Table S10), with one SNP (inside RUFY1) having P<0.05 (binomial P=0.459). 
We did not find evidence for signal enrichment in the 60 independent SNPs found in the 
Psychiatric Genomics Consortium data for ADHD, schizophrenia, bipolar disorder, or major 
depressive disorder63-66 (Table S11).
When we compared 76 (53 independent) SNPs from the AN results with 89 established 
BMI/obesity SNPs,61, 62 five SNPs (inside NEGR1, PTBP2, TMEM18, FTO and MC4R) had 
P<0.05 (binomial P=0.1906). Twenty-six of these 53 SNPs had the same direction of effect 
as originally reported (binomial P value=1) (Table S12). Thirteen of 15 SNPs associated 
with extreme obesity were extracted from our dataset and 9 of these were independent. Four 
of these 9 SNPs had the same direction of effect as originally reported (binomial P value=1) 
(Table S13). Three SNPs (in TMEM18, FTO and MC4R) had P<0.05 (binomial P 
value=0.0084), indicating modest enrichment of nominally associated SNPs from extreme 
obesity in our discovery dataset.
Expression studies
We analyzed RNAseq data for whole-brain tissue obtained from 12 different mouse 
strains(Figure 1). We performed this analysis for 32 mouse orthologues of the 34 human 
genes identified (Table S4). All 32 genes were expressed in the brain, above an average of 2 
FPKM (Fragments Per Kilobase of exon per Million fragments mapped). Specifically, we 
find extremely high expression levels for Ppp3ca (FPKM value 36.40). Further, we find 
high expression for Sox2ot, with an FPKM value of 8.02, and similar expression values for 
Cul3 (10.01) and Ctnna2 (10.79).
Discussion
Given that the evidence base for the treatment of AN remains weak and that no effective 
medications for its treatment exist,20, 67 advances in our understanding of the underlying 
biology of the disorder are essential in order to develop novel therapeutics and to reduce the 
loss of life and diminution of quality of life associated with the disorder. The GCAN/
WTCCC3 investigation represents an unprecedented international genetic collaboration in 
the study of AN, which sets the foundation for further genetic studies.
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Our final global meta-analysis had 80% power to detect SNPs with allele frequency of 0.35 
and genotypic relative risk of 1.15 (α=5×10-8, additive model).68 The AN subtype meta-
analysis had 80% power to detect SNPs with allele frequency of 0.35 and genotypic relative 
risk 1.27 for the AN restricting subtype and 1.28 for the AN binge-purge subtype. Given 
these limitations in power, our strongest indicator that larger sample sizes could detect 
genetic variants associated with AN was revealed in the sign tests. The strong and 
significant evidence for SNP effect sizes in the same direction between discovery and 
replication sets (P=4×10-6) clearly suggests that larger sample sizes could successfully 
identify variants associated with AN and with the AN subtypes potentially enabling 
differentiation on a genetic level between restricting and binge/purge subtypes.
Several genetic variants were suggestively associated with AN (P<10-5) (Table 2). Two 
variants, rs9839776 in SOX2OT and rs17030795 in PPP3CA, were identified through 
analysis of all discovery and replication datasets. Two additional variants with P<10-5, 
rs1523921 located between CUL3 and FAM124B and rs1886797 located near SPATA13, 
were identified through analysis of individuals of European descent only (Table S5), 
suggesting either heterogeneity in the effects of these SNPs by ancestry or low power. The 
genes displayed in Table 2 are discussed in greater detail in the Supplementary Information; 
however, we highlight that four of these variants are neurodevelopmental genes that regulate 
synapse and neuronal network formation (SYN2, NCAM2, CNTNAP2 and CTNNA2) and two 
have been associated with Alzheimer's disease (SOX2OT and PPP3CA). Additionally, one 
of our prioritized SNPs (rs6558000) (Table S5) is located in close vicinity (9kb upstream) of 
the EPHX2 gene that was recently identified as a susceptibility locus to AN through 
candidate gene sequencing study of early-onset severe AN cases and controls.43
Our expression studies further extend the GWAS findings. It is reasonable, althoughperhaps 
not essential, to expect that genes implicated in AN be expressed in the brain. Supporting 
this assumption, 32 mouse orthologues of 34 human genes identified as being of interest 
were expressed at least at a low level in mouse brain. Moreover, genes corresponding to the 
more strongly associated genetic variants tended to be more highly expressed. For example, 
high FPKM values for Ppp3ca, Cul3, and Sox2ot underscore that these genes may play a 
neuropsychiatric role.
AN subtype analyses were included to determine whether differences might exist between 
the classic restricting subtype of AN and the subtype marked by dysregulation characterized 
by binge eating and/or purging behavior. These analyses had lower power due to the smaller 
sample sizes. Only two SNPs, rs1523921 (also found to be suggestively associated in the 
main case-control analysis) and rs10777211 located 333kb upstream of ATP2B1, showed 
association at the 10-5 significance level (Table S6). Similarly, subsequent analyses 
pertaining to associated phenotypes (weight regulation: BMI/obesity loci,40, 61, 69, 70 and 
loci for extreme obesity;61, 71, 72 psychiatric comorbidities: ADHD, schizophrenia, bipolar 
disorder, and major depressive disorder) or previous equivocal association findings for AN 
or eating disorders (AN variants,42 eating disorder related symptoms, behaviors, and 
personality traits variants59, 60) did not reveal significant findings. More adequately powered 
analyses that could allow us to detect variants that can distinguish between these two 
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subtypes could be clinically meaningful in predicting clinical course and outcome and 
eventually in designing targeted therapeutics.
Our understanding of the fundamental genetic architectures of complex medical diseases and 
psychiatric disorders has expanded rapidly.73 It has also become manifestly clear that 
genomic searches for common variation via GWAS can successfully uncover biological 
pathways of etiological relevance. The major limitation to discovery is sample size.74 A 
recent GWAS for schizophrenia reported the identification of 22 genome-wide significant 
loci for schizophrenia (21,000 cases and 38,000 controls), and the results yielded multiple 
themes of clear biological and translational significance (e.g., calcium biology and miR-137 
regulation).75 Moreover, given that cases and controls were derived from multiple sources 
and genotyped on multiple platforms, imputation was essential. Although effective, the 
preferred approach will always be to have samples genotyped on the same platform to 
maximize comparability and the capacity to identify genomic associations.
Although the underlying biology of AN remains incompletely understood, the relative 
homogeneity of the phenotype, replicated heritability estimates, and encouraging results of 
the sign tests presented herein strongly encourage continuing this path of discovery. 
Phenotypic refinement and the identification of biomarkers of illness (independent of 
biomarkers of starvation) could assist with identification of risk loci. We believe that the 
surest and fastest path to fundamental etiological knowledge about the biological basis of 
AN is via GWAS in larger samples.74 This path is notably safe given that it relies on off-the-
shelf technology whose utility has been proven in empirical results for multiple biomedical 
and psychiatric disorders. This approach is cost-effective due to recent sharp decreases in 
genotyping pricing. Therefore, we believe that accrual of large genotyped AN case-control 
samples should be an immediate priority for the field.
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Figure 1. 
Analysis of RNAseq data for whole-brain tissue obtained from 12 different mouse strains for 
32 mouse orthologues of the 34 human genes for which association to anorexia nervosa 
(AN) was identified. The average FPKM (Fragments Per Kilobase of exon per Million 
fragments mapped) values for 32 genes across 12 mouse strains are shown.
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Table 1
List of ethnicities and numbers of samples for main case control and anorexia nervosa 
(AN) subtype analyses across discovery and replication datasets
Country Cases (% of females) AN RESTRICTING subtype 
cases
AN BINGE-PURGE 
subtype cases Controls (% of females)
Discovery dataset*
Canada 54 24 25 417 (46.52)
Czech Republic 72 40 29 331 (35.04)
Finland 131 39 29 404 (100)
France 293 137 135 619 (60.09)
Germany 475 147 55 1,205 (49.13)
Greece 70 10 5 79 (100)
Italy-North 203 103 99 841 (52.19)
Italy-South 75 31 26 52 (100)
Netherlands 348 115 90 593 (51.26)
Norway 82 24 15 602 (67.44)
Poland 175 68 107 564 (29.43)
Spain 186 45 44 185 (75.14)
Sweden 39 28 11 975 (72.10)
UK 213 97 97 5,163 (49.43)
USA 491 311 165 2,830 (41.31)
Total discovery 2,907 1,219 932 14,860 (51.73)
In silico replication
USA-Hakonarson 1,033 (97.67) 0 0 3,775 (45.85)
Estonia 31 (100) 0 0 106 (100)
De novo replication
Austria 48 (100) 0 0 183 (65.03)
Czech Republic 32 (71.88) 0 0 22 (100)
Finland 15 (100) 0 0 94 (8.51)
France 55 (100) 0 0 123 (100)
Germany 174 (99.43) 31 64 380 (66.84)
Greece 16 (100) 0 0 53 (100)
Italy-South 156 (96.79) 32 24 63 (100)
Netherlands 229 (100) 45 23 380 (27.11)
Poland 52 (98.08) 0 0 93 (100)
Spain 10 (100) 0 0 328 (41.46)
UK 155 (100) 28 55 199 (65.83)
USA** 671 (100) 349 272 2,830 (41.31)
Japan 458 (100) 213 240 421 (100)
Total replication 3,135 (98.72) 698 678 9,050 (50.08)
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Country Cases (% of females) AN RESTRICTING subtype 
cases
AN BINGE-PURGE 
subtype cases Controls (% of females)
Total global meta-analysis 5,551 1,606 1,445 21,080
*All AN cases from discovery dataset were females.
**USA samples from discovery dataset were merged together with USA replication samples for replication analysis. The same USA control 
dataset was used.
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